Crossmark

European principles of inhibitor management in patients with haemophilia

Crossref DOI link: https://doi.org/10.1186/s13023-018-0800-z

Published Online: 2018-04-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Giangrande, P. L. F. https://orcid.org/0000-0001-5408-3719
Hermans, C.

O’Mahony, B.

de Kleijn, P.

Bedford, M.

Batorova, A.

Blatný, J.

Jansone, K.
License Information

Text and Data Mining valid from 2018-04-27
More Information

Article History

Received: 5 December 2017

Accepted: 6 April 2018

First Online: 27 April 2018

Ethics approval and consent to participate

: Not applicable.

: PG has received consultancy and/or lecture fees from Bayer, Biotest, CSL Behring, NovoNordisk, Pfizer and Shire within the last year. CH has received consultancy and/or lecture fees from Bayer, CSL Behring, NovoNordisk, Pfizer, Shire, SOBI, LFB, OctaPharma within the last year. MB is currently a member of the Roche/Chugai Haemophilia A Advisory Board and is in receipt of funding from Pfizer for an investigator-initiated research study. JB has received speaker’s fees and/or served as a consultant for NovoNordisk, Shire, Octapharma, Pfizer and Roche within last year. CH, BO’M, PdK, AB and KJ state that they have no competing interests to report.